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Ubiquitin B: an essential mediator of trichostatin
A-induced tumor-selective killing in human
cancer cells
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Although histone deacetylase inhibitors (HDACis) are emerging as a new class of anticancer agents, the mechanism of tumor-
selective killing by HDACi is not well understood. We used suppression of mortality by antisense rescue technique (SMART) to
screen the key genes responsible for the tumor-selective killing by trichostatin A (TSA). Twenty-four genes were identified, the
most significant of which was ubiquitin B (UbB). The expression of UbB was selectively upregulated by TSA in tumor cells, but
not non-malignant cells. Further observation indicated that TSA induced a substantial dissipation of mitochondrial
transmembrane potential, release of cytochrome c into the cytosol, and proteolytic cleavage of caspases-3/9 in HeLa cells,
which was apparently mediated by ubiquitylation and the subsequent degradation of mitochondrial membrane proteins
including BCL-2 and MCL-1. In contrast, knockdown of UbB expression inhibited the TSA-induced apoptotic cascade by
abolishing TSA-induced ubiquitylation and the subsequent degradation of mitochondrial membrane proteins. Furthermore,
apicidine, another HDACi, exhibited activity similar to that of TSA. Interestingly, TSA induced UbB-dependent proteasomal
degradation of BCR–ABL fusion protein in K562 leukemic cells. Thus, our findings highlight the essential role of UbB and UbB-
dependent proteasomal protein degradation in HDACi-induced tumor selectivity. The mechanism provides a novel starting point
for dissecting the molecular mechanism underlying the tumor selectivity of HDACi.
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Histone deacetylase inhibitors (HDACis) are now emerging as
a new class of anticancer agents with potent activity in the
inhibition of proliferation and induction of apoptosis and
differentiation in a wide spectrum of tumors. At least 12
HDACis are under evaluation in over 100 clinical trials and
have produced encouraging therapeutic responses with
surprisingly good safety profiles.1–3 The clinical potential of
HDACis has been well exemplified by the successful
development of Vorinostat, which was recently approved by
the US Food and Drug Administration for treatment of
cutaneous T-cell lymphoma.4 Despite the rapid clinical
progress achieved, the mechanism of action of HDACis is
not yet well understood. One of the central questions is how
these agents selectively kill tumor cells while sparing normal
cells. Identification of the critical intracellular targets respon-
sible for the tumor selectivity of HDACis will further improve
the design of optimized clinical protocols. More attractively,
unraveling the potential ‘death programs’ selectively activated
in tumor but not in normal cells will have broader implications
for the understanding of tumorigenesis and the design of
targeted therapies.
Identification of the target genes essential for the selective
induction of apoptosis in tumor cells has proven to be very
difficult. It is well established that HDACis could affect up to
10% of all known genes at the transcriptional level.5 In addition
to HDACs, many non-histone proteins are also regulated
by HDACis by influencing the molecular events of acetyla-
tion, protein–protein interactions and stability, and so on.
Previously, a significant number of apoptotic and cell-cycle
regulatory genes have been identified by different groups
and proposed to be effectors responsible for the tumor-
selective action of HDACis.6 In acute promyelocytic leukemia,
however, preferential induction of tumor-necrosis factor-
related apoptosis inducing ligand or FAS by HDACis was
proposed to serve as the target responsible for the tumor-
selective action.7 Although these findings have greatly
extended our understanding of the action of HDACis, some
basic questions still remain to be addressed.8,9 One of the
obviously unanswered questions is whether a universal,
essential target responsible for HDACi-mediated apoptosis
exists. To address this, new analytic approaches are needed
to identify the essential genes from the numerous proposed
effectors of HDACis.
Suppression of mortality by antisense rescue technique
(SMART) is a powerful technique to hunt for functionally
relevant genes involved in cell death induced by certain
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agents. The SMART screen used an antisense cDNA
expression library knocking out the global gene expression
of tumor cells in a random and unbiased manner. The
transfected tumor cells are then continuously exposed to
treatment with the agent. The rationale is that the tumor cells
will survive treatment of the agent providing silencing genes
required for the agent-induced apoptosis are inactivated.10 A
number of investigators have successfully applied this
technique in the isolation of death-associated genes involved
in various agent-induced apoptosis.11 In this study, we
performed SMART to identify the key genes responsible for
the tumor-selective action of trichostatin A (TSA), one of most
extensively studied HDACis. We identified 24 genes including
Liv-1 and ubiquitin B (UbB), which were potentially essential
for the TSA-induced apoptosis. Of these, loss of function of
UbB gene conferred the strongest resistance to TSA
treatment. We further underscore the potential role of UbB
in HDACi-induced apoptosis. Our findings highlight a pre-
viously unrecognized mechanism whereby UbB contributes to
the tumor-selective killing of HDACis.
Results
Preferential induction of apoptosis of tumor cells by
TSA. To determine the kinetics and dosage range within
which TSA would preferentially induce apoptosis in tumor
cells, we treated MCF-7 and a non-malignant cell line of
same tissue origin, MCF-10A, with various doses of TSA.
Although TSA caused only slight growth inhibition in MCF-
10A at a dose range between 250 and 1000 nM, it led to
profound growth inhibition of MCF-7 in a dose-dependent
manner. The growth inhibition became evident at 24 h and
reached a maximum at 72 h (Figure 1a). We then chose the
lowest concentration of TSA (250 nM) to compare the
induction of apoptosis in MCF-7 versus MCF-10A.
Exposure of MCF-7 or MCF-10A to TSA displayed a similar
kinetics of apoptosis, which was detectable within 48 h and
peaked at 72 h. At every time point examined, TSA exhibited
preferential induction of apoptosis in MCF-7 (Figure 1b). To
test whether TSA at a dose of 250 nM also preferentially
induced apoptosis in other tumor cell types, tumor (HeLa,
C13K, OV2008) and primary normal respiratory endothelial
cells (RECs) were treated with TSA for 72 h and subjected to
apoptosis analysis. Again, 250 nM TSA preferentially
induced apoptosis in tumor (HeLa, C13K, or OV2008) but
not in REC (Figure 1c). Thus, we concluded that 250 nM TSA
would preferentially induce apoptosis in tumor cells.
Identification of genes essential for TSA-induced
apoptosis using SMART screen. To identify the genes
essential for the preferential induction of apoptosis in tumor
cells, we conducted SMART (Supplementary Figure 1).
Theoretically, only those cells in which ‘death genes’ were
randomly inactivated by the antisense cDNA library could
survive and continue to grow in the presence of HDACi. An
antisense cDNA library was initially generated from TSA-
treated MCF-7 cells, and electroporated into HeLa cells. After
selection with TSA plus hygromycin-B for 4 weeks, the cells
yielded some drug-resistant colonies. Under the same
conditions, cells transfected with the control vector yielded
no surviving colonies. The episomes were recovered for
sequencing. A total 24 cDNA inserts were identified, 6 of
which were selected for in a second round of screening to
confirm the resistance to TSA (Table 1). Of the six vectors
examined, plasmids containing antisense cDNA for UbB
displayed the strongest resistance to TSA. The UbB
antisense plasmid-contained library HeLa cells that
survived the screen were confirmed to be with suppressed
expression of UbB mRNA (Supplementary Figure 2A) and
profound reduction of free cellular ubiquitin (Supplementary
Figure 2B). Transfection of UbB antisense plasmid into HeLa
or MCF-7 cells displayed significant resistance to TSA in the
presence of hygromycin-B (Figure 2a) and provided long-
term survival as defined by clonogenic assays
(Supplementary Table 1). To rule out the possible
interference of hygromycin-B, HeLa or MCF-7 cells were
stably transfected with UbB antisense plasmid and treated
with TSA for 4 days, then examined for growth inhibition.
Again, the cells displayed significant resistance to TSA
treatment compared with HeLa or MCF-7 cells stably
transfected with empty vector (Figure 2b). Furthermore,
stable transfection of HeLa or MCF-7 with UbB antisense
plasmid also made these cells resistant to treatment with
apicidine, a structurally diverse HDACi (Figure 2c). To
address whether the cells expressing UbB antisense
plasmid are also resistant to other cell death triggers, HeLa
cells stably transfected with UbB antisense construct were
exposed to commonly used chemotherapeutic drugs
Figure 1 Preferential induction of apoptosis of tumor cells by TSA. (a) MCF-7
and MCF-10A cells were incubated with TSA at a dose ranging between 250 and
1000 nM for the indicated times. At the end of the experiment, the cells were fixed
and stained with sulforhodamine B. The absorbance at 570 nM of bound dye was
quantified and expressed as a percentage of untreated controls. Each data point is
the mean±standard error (S.E.) of six replicates. (b) MCF-7 and MCF-10A cells
were exposed to 250 nM TSA for the indicated times and then analyzed for
apoptosis using FACS analysis. Each data point represents the mean±S.E
apoptosis percentage of six replicates. (c) Different tumor cell lines (HeLa, C13k,
and OV2008) and non-malignant respiratory endothelial cells (REC) were treated
with 250 nM TSA for 72 h, and the apoptosis percentage was determined using
FACS analysis
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(cisplatin, paclitaxel, or etoposide). UbB antisense construct,
however, did not reduce the sensitivity of HeLa cells
to undergo apoptosis in response to treatment of
chemotherapeutic drugs (Supplementary Figure 2C). These
data indicated that UbB specifically modulated the tumor cell
sensitivity to HDACis but not other cell death triggers.
Next, we examined the influence of TSA on UbB expression
in several tumor and non-malignant cell lines. As shown in
Figure 2d, transcriptional expression of UbB was highly
induced in tumor cells, but not non-malignant cells. The
induction of UbB seems to be gene specific, as expression of
UbC, another member of ubiquitin gene family, was not
Table 1 Positive clones identified from the anti-sense library sorted by their known cellular functions
Clone




2 Thyroid hormone receptor-associated
protein 1
THRAP1 Transcriptional co-activator Induce gene expression N/A
15 High-mobility group nucleosome-binding
domain 1
HMGN1 Altering the interaction
between the DNA and the
histone octamer
Maintains transcribable
genes in a unique
chromatin conformation
Confirmed
112 Peptidylprolyl isomerase A (cyclophilin A) PPIA Encodes a member of the
peptidyl-prolyl cis-trans
isomerase (PPIase) family.
Folding of proteins N/A
335 Cold shock domain containing E1, RNA
binding
CSDE1 RNA chaperones IRES-mediated translation N/A
Protein kinase





66 Ubiquinol-cytochrome c reductase core
protein II
UQCRC2 Protein binding Oxidative phosphorylation N/A




38 Homo sapiens gene for SMAD4 SAMD 4 Transcriptional cofactor
activity
Regulate cell death and
proliferation
Confirmed
42 Mitogen-activated protein kinase kinase
kinase kinase 4








46 Prothymosin, a PTMA Formation, maintenance,







54 Heat shock 90 kDa protein 1, b HSPCB Molecular chaperones Cell stress N/A
58 Tumor rejection antigen (gp96) 1 TRA1 Unknown Cell death N/A
64 Cytochrome c oxidase subunit VIa
polypeptide 1
COX6A1 Catalyzes the electron
transfer from reduced




265 ATP synthase, H+ transporting,
mitochondrial F1 complex, g polypeptide 1






281 Homo sapiens clone CDABP0036 mRNA
sequence
Unknown Unknown Unknown N/A
297 Metastasis-associated lung
adenocarcinoma transcript 1
MALAT1 Unknown Unknown N/A
301 Transmembrane protein 30A TMEM30A Unknown Unknown N/A
B1 Zinc-finger protein 28 (KOX 24) ZNF28 Unknown Unknown N/A
27 Solute carrier family 39 (zinc transporter),
member 6
LIV-1 An integral plasma
membrane protein that





16 Homo sapiens chromosome 8, clone
RP11-44N12
Unknown Unknown Unknown N/A
21 RAB14, member RAS oncogene family RAB14 Member RAS oncogene
family
Unknown Confirmed
81 Homo sapiens BAC clone RP11-143I21
from 7, complete sequence
Unknown Unknown Unknown N/A
242 Ubiquitin B UBB Encodes ubiquitin protein Ubiquitin-mediated
proteolysis
Confirmed
65 Human DNA sequence from clone
RP11-65J3 on chromosome 9
Unknown Unknown Unknown N/A
The positive colonies that have been confirmed describing in ‘Materials and Methods’ N/A, not available (has not been tested)
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induced. Accordingly, elevated level of free cellular ubiquitin
protein was induced in tumor cell, but not non-malignant cells.
The similar induction of UbB and free cellular ubiquitin was
further confirmed by the treatment of apicidine (Supplemen-
tary Figure 2D). Interestingly, the induction of UbB mRNA and
elevation of free cellular ubiquitin seems to be HDACi specific,
with the only exception of UbC mRNA induction by cisplatin, a
number of chemotherapeutic drugs failed to induce expres-
sion of UbB/UbC mRNA and increase free cellular ubiquitin in
HeLa cells (Supplementary Figure 3A). To test whether
knockdown of UbC also prevent apoptosis, HeLa cells
transfected with UbC siRNA were confirmed to be with
reduced expression level of UbC mRNA (data not shown)
and subsequently exposed to TSA or chemotherapeutic
drugs. UbC siRNA, however, did not reduce the sensitivity
of HeLa cells to undergo apoptosis in response to treatment of
TSA or chemotherapeutic drugs (Supplementary Figure 3B).
To determine whether overexpression of UbB directly induced
apoptosis, HeLa, MCF-7, and REC were transiently trans-
fected with UbB expression plasmid and subjected to
apoptosis analysis. Although a significant increase in the
level of the UbB mRNA and free ubiquitin protein was detected
in these cells (Supplementary Figure 4A and B), no obvious
increase in apoptosis was observed (Supplementary Figure
4C). Thus, UbB per se is not sufficient to induce apoptosis. We
then tested whether UbB sensitized tumor cells to TSA-
induced apoptosis. HeLa cells stably transfected with UbB
expression plasmid were much more sensitive to TSA-
induced apoptosis compared with cells stably transfected
with empty vector (54.9±5.4% versus 31.8±3.5%, Po0.01,
Figure 2e), and the similar effects were also observed in MCF-
7 cells (63.3±6.2% versus 32.6±4.7%, Po0.01; Supple-
mentary Figure 4D). On the other hand, transfection of UbB
expression plasmid did not sensitize REC to TSA treatment
(9.1±1.6% versus 8.9±0.9%, P40.05, Figure 2f). There-
fore, overexpression of UbB sensitized tumor cells to TSA.
More importantly, it seems that induced expression of UbB
and consequently elevated level of free cellular ubiquitin
protein are indispensable for TSA-induced apoptosis.
RNAi knockdown of UbB gene suppressed TSA-induced
loss of DWm and apoptosis in HeLa cells. Next, we
examined the effects of UbB depletion on the apoptotic
cascade induced by TSA. UbB siRNA (Supplementary
Figure 2 UbB is an authentic mediator in resistance to TSA-induced apoptosis. (a) HeLa or MCF-7 cells were treated as SMART protocol described, and the surviving
colonies were fixed and stained with SRB. AS-UbB, pCEP4 carrying antisense UbB cDNA. (b) HeLa or MCF-7 cells were stably transfected with pCEP4-CAT (Control) or AS-
UbB and selected with hygromycin-B and reseeded in 96 wells. The cells were then exposed to TSA at a concentration of 500 nM for HeLa or 250 nM for MCF-7. Cell growth
was analyzed at the time points indicated on the x axis. Each data point represents the mean±S.E. of five replicates. (c) HeLa or MCF-7 cells were treated as described in b,
exposed to apicidine at a concentration of 500 nM for HeLa and 250 nM for MCF-7, and analyzed for cell growth. (d) HeLa, MCF-7, REC, or MCF-10A cells were treated with
500 nM TSA for the indicated times and subjected to analysis by real-time PCR for the mRNA levels of UbB and UbC or by western blot for the levels of free cellular ubiquitin
protein. Upper panel: results are expressed as fold induction compared with an untreated or 0 h group, and normalized to that of 18s RNA (the untreated or 0 h group being set
as 1). Lower panel: the levels of free cellular ubiquitin were detected by western blot. HeLa (e) and REC (f) stably transfected with pcDNA3.1-UbB (ubiquitin) or
pcDNA3.1(control) were treated with 500 nM TSA for 48 h, cell apoptosis was analyzed by flow cytometry, values represent the means±S.D. for four experiments. The graphs
represent typical results of cell apoptosis
UbB: essential mediator of TSA-induced apoptosis
P Wu et al
112
Cell Death and Differentiation
Figure 4E) was confirmed to significantly knockdown the
basal and TSA-induced level of UbB mRNA in HeLa cells
(Supplementary Figure 4F) and knockdown effects of UbB
siRNA was confirmed in REC (Supplementary Figure 4G and
H). Accordingly, levels of free cellular ubiquitin were also
significantly reduced by UbB siRNA in HeLa and REC cells
(Supplementary Figure 4I). Considering the mitochondrial
outer membrane permeabilization (MOMP) centers in the
apoptotic process, we examined the effects of UbB depletion
on the dissipation of the mitochondrial transmembrane
potential (DCm) induced by TSA. Although TSA induced a
substantial dissipation of DCm, knockdown of UbB
expression significantly blocked this event (Figure 3a
and b). Consistent with this finding, significant release of
cytochrome c into the cytosol was detected in HeLa cells 16 h
post TSA treatment. After 24 h, TSA treatment caused a
subsequent cleavage of caspases-3 and -9. However,
knockdown of UbB transcription appeared to block the
TSA-induced release of cytochrome c into the cytosol
(Figure 3c) and the subsequent proteolytic cleavage of
caspases-3 and 9 (Figure 3d). These data show that the
induction of UbB is essential for TSA-induced MOMP and the
subsequent apoptotic cascade.
TSA-induced apoptotic cascade is mediated by
ubiquitylation of mitochondrial proteins, which is
inhibited by knockdown of UbB. In light of the finding
indicating that UbB has an essential role in TSA-induced
MOMP, we tested whether TSA and UbB affect ubiquitylation
and the subsequent degradation of mitochondrial proteins.
Treatment of REC with TSA did not induce increase in
polyubiquitylation of total mitochondrial protein (Figure 4a). In
contrast, TSA induced significant polyubiquitylation of total
mitochondrial protein in HeLa cells. Strikingly, TSA-induced
polyubiquitylation was abolished by knocking down UbB
expression, indicating the level of UbB gene expression is
required for the process (Figure 4b). Next, we chose several
mitochondrial proteins, which are pivotal in the control of
MOMP, for further study. Treatment with TSA reduced
endogenous levels of BCL-2 and MCL-1, but not apoptosis
inducing factor (AIF), Bcl-XL, voltage-dependent anion
channels (VDAC), or adenine nucleotide translocator
(ANT). On the other hand, the expression of pro-apoptosis
gene BimEL (the most abundant isoform of Bim) and Bax
was increased moderately on TSA treatment. The MCL-1
and BCL-2 reduction could be abolished by the proteasome
inhibitor MG132 or UbB siRNA, implying proteasomal
degradation is responsible for the action of TSA, and the
induction of UbB gene expression is required for the process
(Figure 4c). In contrast, no obvious change in the expression
levels of the above mitochondria proteins was observed in
REC treated by either TSA, MG132, or UbB siRNA
(Supplementary Figure 5A). To further clarify this, HeLa
cells were transfected with either UbB or control siRNA, and
treated with TSA, total mitochondria proteins from the cells
were then extracted for subsequent polyubiquitylation
analysis. BCL-2 or MCL-1 protein was immunoprecipitated
with antibody against BCL-2 or MCL-1 and examined for
polyubiquitylation with the anti-ubiquitin antibody. Significant
polyubiquitylation of MCL-1 protein was detected in TSA-
treated HeLa cells. Obviously, the TSA-induced
polyubiquitylation of MCL-1 protein was abolished by
transfection of UbB siRNA (Figure 4d). Similarly, on TSA
treatment, BCL-2 polyubiquitylation was also detected in
HeLa cells (Supplementary Figure 5B). In the same
experiment, polyubiquitylation of MCL-1 was not induced in
REC by TSA treatment (Supplementary Figure 5C). On the
other hand, treatment of TSA induced enhanced transcription
of MCL-1and Bim, the levels of BCL-2 and Bcl-XL mRNA
were not affected by TSA treatment in HeLa cells
(Supplementary Figure 5D). Furthermore, in the presence
of cycloheximide (CHX), a protein synthesis inhibitor, the
half-life of MCL-1 protein was significantly shortened by
treatment of TSA (Figure 4e). MCL-1 protein exhibited a half-
life of 48 min in HeLa cells in the absence of TSA. Addition of
TSA accelerated the half-life of MCL-1 protein to 26 min
(Figure 4f). However, the accelerated half-life of MCL-1
protein induced by TSA was reverted by UbB siRNA to
46 min (Figure 4g), indicating the degradation of MCL-1
protein occurs through an ubiquitin/proteasomal mechanism
and the process requires the participation of UbB. To
address whether degradation of MCL-1 is critical for the
TSA-induced apoptotic cascade, we examined the effects of
depletion or overexpression of MCL-1 on the action of TSA.
Figure 3 Knockdown of UbB expression suppresses TSA-induced loss of
DCm and the apoptotic cascade. (a) HeLa cells transfected with UbB siRNA or
control siRNA were treated with 500 nM TSA and subjected to determination of
DCm as defined by fluorescence of J-aggregates emitting at 590 nm. Data
represent the mean of triplicates at each time point. *Po0.01, HeLa transfected
with UbB siRNA versus those transfected with control siRNA. (b) HeLa cells were
treated as described in a; the panel shows representative images of JC-1-stained
cells 16 h after treatment with 500 nM TSA. (c) HeLa cells were transfected with
UbB siRNA or control siRNA and treated with 500 nM TSA for the indicated times.
The cytosolic and mitochondrial fractions of pretreated cells were then analyzed for
levels of cytochrome c. (d) HeLa cells were treated as described in c and analyzed
for cleavage of caspases-3 and -9
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RNA interference dramatically knocked down the
endogenous MCL-1 (Figure 5a). Furthermore, depletion of
MCL-1 sensitized HeLa cells to TSA-induced apoptosis
(Figure 5b) and loss of DCm (Figure 5c and d). On the
other hand, overexpression of MCL-1 could effectively
rescue cells from TSA-induced apoptosis (23.2±4.5%
versus 42.4±3.1%, Po0.01, Figure 5e and f).
As overexpression of UbB alone is not sufficient to induce
apoptosis (Supplementary Figure 4C) and degrade MCL-1
(Supplementary Figure 5E), extra modulators must be
required for the process of cell death. Considering the
chaperone functions of heat shock protein 90 (HSP90) is
affected by acetylation and critical for the stability of many
client proteins, we sought to determine whether HSP90
and UbB cooperated to modulate the degradation of MCL-1
and sensitivity of apoptosis. Interestingly, 17-allylamino
17-demethoxygeldanamycin (17-AAG), a HSP90 inhibitor,
selectively degraded MCL-1 in HeLa but not in non-malignant
cells. Although overexpression/knockdown of UbB alone did
not affect the protein levels of MCL-1, the 17-AAG-induced
degradation of MCL-1 could be abolished by UbB siRNA
(Supplementary Figure 5E). Furthermore, 17-AAG-induced
G2/M cell-cycle arrest and apoptosis in HeLa cells could
be profoundly reverted by UbB siRNA (Supplementary
Figure 5F–H). These data strongly imply that HSP90 and
UbB cooperate to mediate the degradation of MCL-1 and
apoptosis.
The action of TSA could be mimicked by other HDAC
inhibitors and TSA-induced degradation of other
oncogenic proteins is dependent on expression of
UbB. We have shown that TSA induces apoptotic cascade
through an unknown UbB-dependent proteasomal
degradation of mitochondria proteins. Next, we tested
whether the action is TSA specific, or is shared with other
HDAC inhibitors, and whether TSA induces an UbB-
dependent proteasomal degradation of oncogenic proteins
other than mitochondrial proteins. Similarly, apicidine
reduced the endogenous levels of BCL-2 and MCL-1 but
not Bim, Bax, Bcl-XL, AIF, VDAC, and ANT in HeLa cells
(Figure 6a). Again, the reduction could be abolished by
MG132 and UbB siRNA, indicating UbB-dependent
proteasomal degradation of mitochondrial protein might be
a common mechanism of action shared by other HDAC
inhibitors. Previously, some investigators had shown the
proteasomal degradation of BCR–ABL fusion protein after
HDACi treatment.12 To address whether expression of UbB
is required for TSA-induced proteasomal degradation of
BCR–ABL, the leukemia cell line, K562 was treated with TSA
and examined for the reduction of BCR–ABL fusion protein.
TSA reduced the level of BCR–ABL but not MCL-1 protein in
a time- and dose-dependent manner in K562 cells
(Figure 6b). Apparently, reduction of BCR–ABL was not
because of inhibition of BCR–ABL at transcriptional level
(Figure 6c). Although expression of UbB mRNA was not
Figure 4 TSA induced UbB-dependent degradation of mitochondrial proteins through an ubiquitin/proteasomal mechanism. (a) REC cells were treated with 500 nM TSA
or PBS for 12 h and the proteasome inhibitor MG132 (20 mM) was added 6 h before cell collection. Total 80mg mitochondrial proteins were isolated and analyzed for
ubiquitylation using anti-ubiquitin antibody. (b) HeLa cells transfected with UbB siRNA or control siRNA were treated as described in a and analyzed for ubiquitylation of
mitochondrial proteins. Con siRNA, control siRNA. (c) HeLa cells were treated as described in a, collected for extraction of mitochondrial proteins, and analyzed for MCL-1,
BCL-2, BimEL, Bax, Bcl-XL, AIF, VDAC, and ANT protein levels. (d) HeLa cells were treated as described in a, 200mg of total mitochondria protein was subjected to
immunoprecipitation using anti-MCL-1 antibody. The immunoprecipitates were subjected to western blot analysis with anti-ubiquitin antibody. Con siRNA, control siRNA.
(e) HeLa cells transfected with UbB siRNA or control siRNA were preincubated for 1 h with 500 nM TSA or PBS. The cells were then incubated with 200mg/ml of the protein
synthesis inhibitor cycloheximide (CHX) for the indicated times. The cells were collected and subjected to western blot analysis for protein levels of MCL-1. MCL-1 protein half-
life of control siRNA transfected cells (f) and UbB siRNA transfected cells (g) was determined, the graph represents MCL-1/action ratio levels as measured by densitometry,
MCL-1 levels at time 0 h were calculated as 100%, and data averaged from three experiments are shown. Error bars represent standard deviation
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induced, level of free cellular ubiquitin significantly increased
after TSA treatment (Figure 6d). Again, the reduction of
BCR–ABL protein was blocked by UbB siRNA or MG132
(Figure 6e), indicating the proteasomal degradation of
oncogenic protein other than mitochondrial proteins also
requires the participation of UbB. Notably, K562 cells were
resistant to TSA-induced apoptosis in the experiment
(Figure 6f), and in contrast to previous TSA-sensitive cell
lines, upregulation of free cellular ubiquitin in K562 failed to
degrade MCL-1 protein, indicating these two events could be
dissociated.
Discussion
Significant advances in clinical trials involving the use of
HDACis have been achieved; nevertheless, the mechanism of
action of these agents is not yet well understood. One of the
key questions is whether there are universal, essential targets
responsible for the tumor-selective action of HDACis.13 Iden-
tification of these putative tumor-associated ‘death programs’
selectively activated by HDACis is fundamentally important.14
To address this, we conducted a SMART analysis on a
genome-wide scale in this study. The obvious advantage of
the current approach is that it allows potential effectors pivotal
to TSA-induced apoptosis to be identified in an unbiased and
random manner. Twenty-four positive hits were identified by
virtue of the induced resistance to TSA-induced apoptosis.
These genes provide interesting primary data for a deeper
understanding of the mechanism of action of HDACi and the
critical molecular events leading to tumor cell survival.
One of the most significant hits is UbB, one of the ubiquitin
gene family members. Ubiquitin is a small, highly conserved
protein expressed in all eukaryotic cells, and can be covalently
linked to certain target proteins to mark them for degradation
by the ubiquitin-proteasome system (UPS). The abundance of
cellular ubiquitin is in a dynamic balance, which is ultimately
maintained by de novo synthesis of ubiquitin from ubiquitin
gene transcripts. Human ubiquitin is encoded by a family of
multiple genes, composed of UbA52, UbA80, UbB, and
UbC, of which UbB and UbC are inducible by various cell
stresses.15–18 Up to now, the role of UPS in apoptosis
has been extensively investigated, and ubiquitin-activating
enzyme (E1), ubiquitin conjugating enzymes (E2s),
ubiquitin ligases (E3s), and proteasomes have been well
characterized.19 On the other hand, knowledge of the role of
the ubiquitin gene family in regulating various cellular
functions has been generally poor and overlooked owing to
the assumption that these genes would not determine the
specificity of ubiquitylation. One of the first reports linking the
process of ubiquitylation with apoptosis emerged from studies
of intersegmental muscle programed cell death in the tobacco
hawkmoth, Manduca Sexta.20 Further evidence for the
involvement of ubiquitin genes in apoptosis came from studies
of murine lymphocytes treated with teniposide.21 However,
the finding that HDACi activates UbB and favors apoptosis by
elevating the UbB transcription and level of free cellular
ubiquitin selectively in tumor cells has not been recognized
earlier. Indeed, identification of UbB as the essential regulator
in selective apoptosis of tumor cells is somehow unanticipated
in that UbB was believed to be ubiquitously abundant in both
normal and tumor cells. Subsequent to the selective induction
of UbB, several mitochondrial proteins pivotal to the control of
MOMP were degraded through activation of the UPS in tumor
cells. Obviously, TSA-induced proteasomal degradation of
mitochondrial proteins is gene specific, rather than a global
effect because not all mitochondrial proteins examined were
affected. Notably, the action of UbB could be duplicated in
various tumor cell types using structurally diverse HDAC
inhibitors but not commonly used chemotherapeutic drugs,
indicating UbB probably represents one of the universal key
targets responsible for HDACi-induced selective apoptosis in
various tumors.
Figure 5 MCL-1 is a critical regulator of TSA-induced loss of DCm and
apoptosis. (a) HeLa cells were transfected with MCL-1 or control siRNA. The levels
of MCL-1 in whole-cell lysates were determined by western blotting. HeLa/Con,
HeLa cells transfected with control siRNA; HeLa siRNA, HeLa cells transfected with
MCL-1 siRNA. (b) HeLa cells were transfected with MCL-1 siRNA and exposed to
500 nM TSA for 48 h. The cells were then stained with propidium iodide and annexin
V-FITC, and analyzed by flow cytometry. Results are presented as the
means±S.D. of triplicates. (c) HeLa cells transfected with control or MCL-1 siRNA
were treated with 500 nM TSA for 24 h, and then stained with JC-1; the panel shows
representative photomicrographs of JC-1-stained cells. (d) Quantitation of the
percentage of cells staining positive for J-aggregates was analyzed by flow
cytometry. *Po0.05, HeLa cells transfected with MCL-1 siRNA versus with control
siRNA. (e) V5-tagged MCL-1 or empty control vector was introduced into HeLa cells.
Three days after transfection, MCL-1 was determined by western blot. HeLa/Con,
HeLa cells transfected with pcDNA3.1/V5-His-TOPO; HeLa/MCL-1, HeLa cells
transfected with pcDNA3.1-V5tagged MCL-1. (f) HeLa cells were treated as
described in e and were exposed to 500 nM TSA for 48 h, cell apoptosis was
analyzed by flow cytometry, and values represent the means±S.D. of four
experiments. The graphs represent typical results of cell apoptosis
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Recently, accumulating evidence suggested that HDACis
may regulate apoptosis by decreasing the half-life of several
oncogenic proteins through activating the proteasomal
degradation pathway.22,23 However, whether the proteasomal
degradation of oncogenes represents a general mechanism
central to HDACi-induced apoptosis was not systematically
evaluated on a genome-wide scale. Thus, our present finding
that UbB works as a universal key target responsible for
HDACi-induced selective apoptosis in tumor cells is a novel
and important concept. Up to now, it is not known that the
exact mechanism whereby HDACi could selectively activate
expression of UbB, and subsequently target only key anti-
apoptotic mitochondrial proteins for proteasomal degradation
in tumor but not in non-malignant cells. In our hands, HSP90
and UbB cooperate to mediate the degradation of MCL-1 and
apoptosis in Hela cells, indicating HSP90 and acetylation-
dependent release of client proteins might have functions in
the process.24–26 In contrast, our data in K562 clearly highlight
that in the leukemia cell line TSA instead induces the UbB-
dependent degradation of BCR–ABL but not MCL-1. The lack
of MCL-1 degradation seems to correlate with the resistance
of these cells to HDACi-induced apoptosis. These findings
might suggest BCR–ABL is a more abundant/critical HSP90
client protein than MCL-1 in K562 cells. Most recently, an
independent group had used a genome-wide loss-of-function
screen to identify HR23B, which shuttles ubiquitinated cargo
proteins to the proteasome, as a sensitivity determinant for
HDAC inhibitor-induced apoptosis.27 These findings strongly
imply aberrant profiles of components mediating proteasomal
degradation pathway including HSP90, HDAC6, HR23B, and
UbB proposed by us would be cooperated to form the
molecular basis responsible for the HDACi selectivity. Our
study is now underway to test the hypothesis.
Materials and Methods
Cells and constructs. MCF-7 cells were cultured in phenol red-free Eagle’s
minimal essential medium supplemented with 5% charcoal-stripped fetal bovine
serum and 1011 M estradiol while being treated with TSA. Cells were grown in
phenol red-free medium 24 h before treatments were initiated. The breast epithelial
cell line, MCF-10A, was obtained from ATCC (Manassas, VA, USA) and cultured in
DMEM/F12 supplemented with 20 ng/ml epidermal growth factor, 100 ng/ml cholera
toxin, 0.01 mg/ml insulin, 500 ng/ml hydrocortisone, and 5% horse serum. A
cisplatin-sensitive ovarian cancer cell line (OV2008) and its resistant variant (C13K)
were gifts from Dr. Rakesh Goel from the Ottawa Regional Cancer Center, Ottawa,
Canada and cultured as described earlier.28 Primary normal RECs were isolated
from freshly excised human nasal polyp tissue using the protease method.29 The
proteasome inhibitor, MG132, was from Calbiochem (San Diego, CA, USA); CHX,
TSA, and apicidine were from Sigma (St. Louis, MO, USA). Constructs encoding
full-length MCL-1 were kindly provided by Ulrich Maurer (Institut fur Molekulare
Medizin und Zellforschung, Albert-Ludwigs-Universitat, Freiburg, Germany). The
pOTB7-UbB was from Proteintech Group, Inc. (Chicago, IL, USA) and subcloned
into pcDNA3.1 (þ ). Antibodies to MCL-1, AIF, ANT, and b-actin were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA); to Bax and cytochrome c
were purchased from Neomarker (Neomarker, Fremont, CA, USA); to VDAC were
Figure 6 HDAC inhibitor apicidine mimics the action of TSA, and TSA induces degradation of BCR–ABL fusion protein is dependent on expression of UbB. (a) HeLa cells
were transfected with UbB or control siRNA, treated with 500 nM apicidine for 12 h, and MG 132 (20mM) was added 6 h before cell collection. Mitochondrial protein was
extracted and examined for the protein levels of genes as indicated. (b) K562 cells were exposed to 200 nM TSA for the indicated times (left panel), or the indicated dose of
TSA for 16 h (right panel). Protein levels of BCR–ABL and MCL-1 in K562 cells were determined by western blot analysis. (c) K562 cells were incubated with 500 nM TSA for
the indicated times and subjected to analysis of BCR–ABL mRNA by real-time PCR. Values were expressed as fold induction compared with the untreated or 0 h group. Error
bars represent the S.E.M. of five replicates. (d) K562 cells were treated with 500 nM TSA for the indicated times. Levels of UbB/UbC mRNA and free cellular ubiquitin protein
were examined. Upper panel: levels of UbB/UbC mRNA are expressed as fold induction compared with the untreated or 0 h group. Lower panel: the levels of free cellular
ubiquitin were detected by western blot. (e) K562 cells transfected with UbB or control siRNA were treated with 500 nM TSA for 16 h, and MG 132 (20 mM) was added 6 h
before cell collection. Protein levels of BCR–ABL in K562 were determined by western blot. (f) K562 cells were exposed to TSA for 16 h then subjected to apoptosis analysis.
Error bars represent the S.E.M. of five replicates
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purchased from Biovision (Biovision, Mountain View, CA, USA); to Bim, BCL-2, Bcl-
XL, BCR-ABL, caspases-3 and -9 were purchased from Cell Signaling Technology
(Cell Signaling Technology, Beverly, MA, USA).
Cell growth assay. Pretreated cells were plated in 96-well plates and cell
growth was monitored following our previous description.30 Briefly, the cells were
fixed with 10% trichloroacetic acid (TCA) and were stained with 0.4%
sulforhodamine B (SRB, Sigma) in 1% acetic acid for 1 h at the end of the
experiment. One control plate was fixed with TCA 8 h after plating to determine the
absorbance representing the starting cell number. When expressed as a
percentage of the value for untreated controls, an increase in cell number falls
on the positive scale and a decrease in cell number appears on the negative scale.
Annexin-V binding assays were performed using a commercially available kit
(PharMingen, San Diego, CA, USA) according to the manufacturer’s
recommendation.
Suppression of mortality by antisense rescue
technique. Construction of an antisense cDNA library and subsequent
analysis using SMART were performed following protocols described elsewhere
with some modifications.10 Initially, at 0, 8, 12, 24, 36, and 48 h post treatment with
250 nM TSA, MCF-7 cells were collected and total mRNA was extracted for
construction of antisense cDNA libraries by random insertion of cDNA into the
mammalian replication permissive plasmid, pCEP4. Forty micrograms of library
DNA containing approximately 2 106 cDNA inserts of various sizes was
electroporated into 1 107 HeLa cells. The HeLa cells transfected with the cDNA
library were then selected by incubation with 150 nM TSA in the presence of 200mg/
ml hygromycin-B for 4 weeks. Parallel plates of cells transfected with pCEP4-CAT
were similarly selected. The culture medium was changed, and TSA was re-added
daily for the first week, and then every other day for the remaining weeks. At the end
of 4 weeks of selection, the surviving colonies were pooled and amplified in the
presence of hygromycin-B(200mg/ml) for isolation of plasmids using the Hirt DNA
extraction method.31 The isolated DNA was digested with Dpn I and electroporated
into Escherichia coli DH10B. The resultant colonies were picked up and screened by
restriction enzyme digestion to detect the presence of inserts. The individual
plasmids with inserted antisense cDNA were subjected to a second round of
selection to confirm the resistance to TSA treatment. The cells were then selected
with TSA (150 nM) and hygromycin-B (200mg/ml) for 20 days. Episomes that were
confirmed to be TSA resistant were chosen for DNA sequencing and further
characterization.
Determination of the mitochondrial transmembrane potential
(DWm). Pretreated cells were stained with JC-1 (5, 50, 6, 60-tetrachloro-1, 10, 3, 30-
tetraethylbenzimidazolcar bocyanine iodide; Molecular Probes, Eugene, OR, USA),
analyzed by flow cytometry, and visualized as described earlier.32
Subcellular fractionation. Cells were lysed in mitochondria lysis buffer
[210 mmol/l mannitol, 70 mmol/l sucrose, 10 mmol/l HEPES (pH 7.4), 1 mmol/l
EDTA, and protease inhibitor cocktail] with a Dounce homogenizer and subjected to
centrifugation at 1000 g to pellet nuclei. Postnuclear supernatant was centrifuged
at 10 000 g to pellet the mitochondria-enriched heavy membrane fraction, and the
resulting supernatant was further centrifuged to obtain the cytosolic fraction.
Half-life assay. HeLa cells were plated in 100 mm plates, the cells were
preincubated for 1 h with 500 nM TSA, then treated with 120mg/ml CHX for 0, 15,
30, 60, 90, 120, and 150 min. The cells were collected, and 50 mg of protein lysate
was separated on a 12% SDS-PAGE, transferred to membranes, and probed with
anti-MCL-1 polyclonal antibodies. The protein levels were calculated as mentioned
above, and the values of MCL-1were plotted against the values of actin. The values
of MCL-1/actin at time 0 were taken as 100%.
RNA interference. Annealed, purified, and desalted double-stranded siRNA
MCL-1 (AAG AAA CGC GGU AAU CGG ACU) and UbB (UGG GCA CUG CGA
AUG CCA UGA CUG A; AAU GGC UAU AGU GCA GAG UAA UGC C; UUU GAA
CAG GUU CAG CUA UUA CUG A) and UbC (GGU GAA CGC CGA UGA UUA U)
and control siRNA were ordered from Invitrogen Corporation (Carlsbad, CA, USA).
Then, 1.5 105 cells were plated per well in a 6-well dish on day 0. On day 1, the
cells were transfected with 200 nM siRNA in Opti-MEM medium (Invitrogen) without
FBS using Lipofectamine 2000 reagent (Invitrogen).
Real-Time PCR. Quantitative PCR was performed using the SYBR Green Real
Time PCR method. Each sample was tested in triplicate, and relative gene
expression was analyzed using the 2DDCT method,33 and the results expressed as
fold induction compared with the untreated group. PCR was performed with a 50
sense primer (50-GGT GAG CTT GTT TGT GTC CCT GT-30) and a 30 antisense
primer (50-TCC ACC TCA AGG GTG ATG GTC-30) for UbB; a 50 sense primer
(50-TGC ACC TGG TAC TCC GTC TCA-30) and a 30 antisense primer (50-CAG TGA
GTG TCT TCA CGA AGA TTT G-30) for UbC; a 50 sense primer (50-GTG GAG TTC
TTC CAC GTA CAG GA-30) and a 30 antisense primer (50-AGC AAC ACC CGC
AAA AGC-30) for MCL-1; a 50 sense primer (50-CGT GTG TGA AAC TCC AGA CTG
TCA-30) and a 30 antisense primer (50-CTT CAG CGG CCA GTA GCA TCT-30) for
BCR–ABL. A 50 sense primer (50-AGC ACC CAT GAG TTG TGA CAA ATC-30) and
a 30 antisense primer (50-CGT TAA ACT CGT CTC CAA TAC GC-30) for Bim; a 50
sense primer (50-GTA AAC TGG GGT CGC ATT GT-30) and a 30 antisense primer
(50-TGC TGC ATT GTT CCC ATA GA-30) for Bcl-XL; a 5
0 sense primer (50-TCG
CCC TGT GGA TGA CTG AG -30) and a 30 antisense primer (50-CAG AGT CTT
CAG AGA CAG CCA GGA -30) for BCL-2; To amplify 18s RNA internal control, a 50
sense primer (50- AGT CCC TGC CCT TTG ACA CA -30) and a 30 antisense primer
(50-GAT CCG AGG GCC TCA CTA AAC-30) were used.
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